Selected as a C-Further program with up to ~$1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial ...
Please provide your email address to receive an email when new articles are posted on . Aviceda Therapeutics secured $207.5 million in Series C financing to advance the AVD-104 program in geographic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results